(Q34092284)

31 July 2017

Cryptococcal Meningitis in HIV-Infected Patients (English)

1 reference

31 July 2017

1 reference

cryptococcal meningitis

1 reference

Powderly WG

1

1 reference

31 July 2017

1 August 2000

1 reference

Current infectious disease reports

31 July 2017

1 reference

31 July 2017

2

1 reference

31 July 2017

4

1 reference

31 July 2017

352-357

1 reference

Effects of antifungal agents and gamma interferon on macrophage cytotoxicity for fungi and tumor cells

31 July 2017

1 reference

https://api.crossref.org/works/10.1007%2FS11908-000-0015-Y

Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-000-0015-Y

Changes in AIDS-defining illnesses in a London Clinic, 1987-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-000-0015-Y

Cryptococcal meningitis and AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-000-0015-Y

Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-000-0015-Y

Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus-associated Cryptococcosis. Cryptococcal Disease Active Surveillance Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-000-0015-Y

Mediastinal lymphadenitis due to cryptococcal infection in HIV-positive patients on highly active antiretroviral therapy

21 January 2018

1 reference

12 December 2020

Use of cerebrospinal fluid shunt for the management of elevated intracranial pressure in a patient with active AIDS-related cryptococcal meningitis

1 reference

12 December 2020

A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group

1 reference

12 December 2020

Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group

1 reference

12 December 2020

Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis.

1 reference

12 December 2020

Serotypes of Cryptococcus neoformans in patients with AIDS

1 reference

12 December 2020

Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group

1 reference

12 December 2020

Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis

1 reference

12 December 2020

1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA)

1 reference

12 December 2020

Cells and cytokines in pulmonary cryptococcosis

1 reference

12 December 2020

Early mycological treatment failure in AIDS-associated cryptococcal meningitis

1 reference

12 December 2020

Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS.

1 reference

12 December 2020

Low-dose fluconazole as primary prophylaxis for cryptococcal infection in AIDS patients with CD4 cell counts of < or = 100/mm3: demonstration of efficacy in a positive, multicenter trial

1 reference

12 December 2020

Cytokine profiles of AIDS patients are similar to those of mice with disseminated Cryptococcus neoformans infection

1 reference

12 December 2020

Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing

1 reference

12 December 2020

Cryptococcal pneumonia in AIDS: is cryptococcal meningitis preceded by clinically recognizable pneumonia?

1 reference

12 December 2020

Quantitative and qualitative differences in the serum antibody profiles of human immunodeficiency virus-infected persons with and without Cryptococcus neoformans meningitis

1 reference

12 December 2020

Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS

1 reference

12 December 2020

Antibody immunity and invasive fungal infections

1 reference

12 December 2020

Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group

1 reference

12 December 2020

The Ecology of Cryptococcus neoformans and the Epidemiology of Cryptococcosis

1 reference

12 December 2020

Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome

1 reference

12 December 2020

HIV combination therapy: partial immune restitution unmasking latent cryptococcal infection

1 reference

12 December 2020

A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group

1 reference

12 December 2020

Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without human immunodeficiency virus infection

1 reference

12 December 2020

Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups

1 reference

12 December 2020

Epidemiological evidence for dormant Cryptococcus neoformans infection

1 reference

12 December 2020

Serum cryptococcal antigen in patients with AIDS

1 reference

12 December 2020

Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period.

1 reference

12 December 2020

Recent advances in biology and immunology of Cryptococcus neoformans

1 reference

12 December 2020

Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease.

1 reference

12 December 2020

Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group

1 reference

12 December 2020

Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans

1 reference

12 December 2020

HIV combination therapy: immune restitution causing cryptococcal lymphadenitis dramatically improved by anti-inflammatory therapy

1 reference

12 December 2020

Polysaccharide antigen in brain tissue of AIDS patients with cryptococcal meningitis

1 reference

12 December 2020

Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome

1 reference

12 December 2020

A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group

1 reference

12 December 2020

Clinical and Host Differences Between Infections with the Two Varieties of Cryptococcus neoformans

1 reference

12 December 2020

Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans

1 reference

12 December 2020

10.1007/S11908-000-0015-Y

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11095877